Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey

Introduction Imraldi™ is a biosimilar of the anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab and was recently approved in Europe for the treatment of various inflammatory conditions. Imraldi is administered via an autoinjector device that features distinct design attributes compared...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology and therapy. 2019-06, Vol.6 (2), p.195-206
Main Authors: Fenwick, Steve, Thakur, Kunal, Munro, Duncan
Format: Article
Language:English
Subjects:
Adalimumab
Autoinjector
Biosimilar
Bowel disease
Drug therapy
Family Medicine
General Practice
Humira
Immunotherapy
Imraldi
Inflammatory bowel disease
Inflammatory diseases
Internal Medicine
Medicine
Medicine & Public Health
Monoclonal antibodies
Nurses
Original Research
Orthopedics
Patients
Quality of Life Research
Rheumatology
TNF inhibitors
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Imraldi™ is a biosimilar of the anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab and was recently approved in Europe for the treatment of various inflammatory conditions. Imraldi is administered via an autoinjector device that features distinct design attributes compared with other biologic TNF inhibitor autoinjectors, such as the Humira (adalimumab) Pen® and Enbrel® (etanercept) MyClic® Pen were developed by the relevant pharmaceutical companies. The aim of this study was to evaluate patients’ and nurses’ preferences for the Imraldi versus Humira or Enbrel MyClic autoinjectors in the UK and Germany. Methods Patients with inflammatory joint or bowel disease and nurses with experience in educating patients with these conditions on self-injection participated in two survey studies, the first comparing the Imraldi and Humira autoinjectors and the second comparing the Imraldi and Enbrel MyClic autoinjectors. Results Overall, 101 nurses (UK, n  = 50; Germany, n  = 51) and 151 patients (UK, n  = 90; Germany, n  = 61) participated in both studies. In the first study, 85% of nurses and 78% of patients preferred the Imraldi autoinjector over the Humira autoinjector ( P  
ISSN:2198-6576
2198-6584
DOI:10.1007/s40744-019-0144-8